1st Quarter - Report

EMD SERONO, INC. for EMD SERONO INC

Firm
Client
Income
—
Expenses
$500,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

10 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

General Discussions related to National Institutes of Health funding

LobbyistCovered position, as disclosed
STEPHANIE FRYE (FORMERLY SALVAGNO) —

Contacted: SENATE; Food & Drug Administration (FDA); Environmental Protection Agency (EPA); U.S. Trade Representative (USTR); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Chemicals/Chemical Industry CHM

General discussions related to Polyfouroalyl/Perflourooctanesulfonic Acid (PFAS/PFOS) General discussions regarding the Toxic Substances Control Act; provisions related to Section 5/Pre-Manufacture Notice (PMN)

LobbyistCovered position, as disclosed
STEPHANIE FRYE (FORMERLY SALVAGNO) —

Contacted: HOUSE OF REPRESENTATIVES; Environmental Protection Agency (EPA); Executive Office of the President (EOP); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); SENATE

Labor Issues/Antitrust/Workplace LBR

General discussions regarding workplace development

LobbyistCovered position, as disclosed
STEPHANIE FRYE (FORMERLY SALVAGNO) —

Contacted: U.S. Trade Representative (USTR); Executive Office of the President (EOP); SENATE; Environmental Protection Agency (EPA); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Science/Technology SCI

General discussions related to semiconductors

LobbyistCovered position, as disclosed
STEPHANIE FRYE (FORMERLY SALVAGNO) —

Contacted: U.S. Trade Representative (USTR); Environmental Protection Agency (EPA); Executive Office of the President (EOP); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

General discussions regarding United States-Switzerland Free Trade Agreement General discussions regarding United States-European Union Free Trade Agreement General discussions regarding Section 301 tariffs and product exclusions applications

LobbyistCovered position, as disclosed
STEPHANIE FRYE (FORMERLY SALVAGNO) —

Contacted: HOUSE OF REPRESENTATIVES; Environmental Protection Agency (EPA); Food & Drug Administration (FDA); SENATE; Executive Office of the President (EOP); U.S. Trade Representative (USTR)

Taxation/Internal Revenue Code TAX

General discussions regarding the repeal of Internal Revenue Code Section 385 regulations General discussions regarding Global Intangible Low Tax Income (GILTI) General discussions regarding Base Erosion and Anti-Abuse Tax (BEAT)

LobbyistCovered position, as disclosed
STEPHANIE FRYE (FORMERLY SALVAGNO) —

Contacted: Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Environmental Protection Agency (EPA); SENATE

Health Issues HCR

H.R. 3: Elijah E. Cummings Lower Drug Costs Now Act; all provisions of the bill H.R. 19: Lower Costs, More Cures Act of 2019; all provisions of the bill H.R. 6201: Families First Coronavirus Response Act; provisions related to healthcare S. 2543: Prescription Drug Pricing Reduction Act of 2019; all provisions of the bill S. 3129: Lower Costs, More Cures Act of 2019; all provisions of the bill S. 3537: Protecting Our Pharmaceutical Supply Chain from China Act of 2020; all provisions of the bill S. 3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act; provisions related to healthcare 2021 Notice of Benefit and Payment Parameters Proposed Rule (Draft) 21st Century Cures Act 2.0; all healthcare provisions of the draft General discussions regarding support for, and importance of, care giving General healthcare issues surrounding the COVID-19 pandemic

LobbyistCovered position, as disclosed
MALLORI ANNE MERANDINO —
WENDY SUSSMAN —

Contacted: SENATE; U.S. Trade Representative (USTR); Environmental Protection Agency (EPA); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: H.R. 6201 (116th), S. 3548 (116th), S. 2543 (116th), S. 3129 (116th), H.R. 3 (116th), S. 3537 (116th), H.R. 19 (116th)

Medicare/Medicaid MMM

H.R. 3: Elijah E. Cummings Lower Drug Costs Now Act; all provisions of the bill H.R. 19: Lower Costs, More Cures Act of 2019; all provisions of the bill H.R. 6201: Families First Coronavirus Response Act; provisions related to healthcare S. 2543: Prescription Drug Pricing Reduction Act of 2019; all provisions of the bill S. 3129: Lower Costs, More Cures Act of 2019; all provisions of the bill S. 3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act; provisions related to healthcare 2021 Notice of Benefit and Payment Parameters Proposed Rule General healthcare issues surrounding the COVID-19 pandemic

LobbyistCovered position, as disclosed
MALLORI ANNE MERANDINO —
WENDY SUSSMAN —

Contacted: HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Environmental Protection Agency (EPA); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); SENATE

Bills named: H.R. 3 (116th), H.R. 6201 (116th), S. 3548 (116th), S. 3129 (116th), S. 2543 (116th), H.R. 19 (116th)

Animals ANI

General discussions regarding Predictive Toxicology Roadmap

LobbyistCovered position, as disclosed
STEPHANIE FRYE (FORMERLY SALVAGNO) —

Contacted: Environmental Protection Agency (EPA); SENATE; Food & Drug Administration (FDA); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Pharmacy PHA

H.R. 3: Elijah E. Cummings Lower Drug Costs Now Act; all provisions of the bill H.R. 19: Lower Costs, More Cures Act of 2019; all provisions of the bill H.R. 6201: Families First Coronavirus Response Act; provisions related to healthcare S. 2543: Prescription Drug Pricing Reduction Act of 2019; all provisions of the bill S. 3129: Lower Costs, More Cures Act of 2019; all provisions of the bill S. 3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act; provisions related to healthcare 2021 Notice of Benefit and Payment Parameters Proposed Rule General healthcare issues surrounding the COVID-19 pandemic

LobbyistCovered position, as disclosed
MALLORI ANNE MERANDINO —
WENDY SUSSMAN —

Contacted: Executive Office of the President (EOP); SENATE; Environmental Protection Agency (EPA); U.S. Trade Representative (USTR); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: S. 3129 (116th), H.R. 6201 (116th), S. 2543 (116th), H.R. 3 (116th), H.R. 19 (116th), S. 3548 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.